The structure-guided discovery of osimertinib: the first US FDA approved mutant selective inhibitor of EGFR T790M

被引：38

作者：

Butterworth, Sam ^{[1
]}

Cross, Darren A. E. ^{[1
]}

Finlay, Raymond V. ^{[1
]}

Ward, Richard A. ^{[1
]}

Waring, Michael J. ^{[1
]}

机构：

[1] AstraZeneca, Darwin Bldg,310 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WG, England

来源：

MEDCHEMCOMM | 2017年 / 8卷 / 05期

关键词：

LUNG-CANCER; RESISTANCE; RECEPTOR; AZD9291;

D O I：

10.1039/c7md90012k

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：820 / 822

页数：3

共 4 条

[1] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[2] Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor [J].

Finlay, M. Raymond V. ;

Anderton, Mark ;

Ashton, Susan ;

Ballard, Peter ;

Bethel, Paul A. ;

Box, Matthew R. ;

Bradbury, Robert H. ;

Brown, Simon J. ;

Butterworth, Sam ;

Campbell, Andrew ;

Chorley, Christopher ;

Colclough, Nicola ;

Cross, Darren A. E. ;

Currie, Gordon S. ;

Grist, Matthew ;

Hassall, Lorraine ;

Hill, George B. ;

James, Daniel ;

James, Michael ;

Kemmitt, Paul ;

Klinowska, Teresa ;

Lamont, Gillian ;

Lamont, Scott G. ;

Martin, Nathaniel ;

McFarland, Heather L. ;

Mellor, Martine J. ;

Orme, Jonathon P. ;

Perkins, David ;

Perkins, Paula ;

Richmond, Graham ;

Smith, Peter ;

Ward, Richard A. ;

Waring, Michael J. ;

Whittaker, David ;

Wells, Stuart ;

Wrigley, Gail L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) :8249-8267

[3] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[4] Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) [J].

Ward, Richard A. ;

Anderton, Mark J. ;

Ashton, Susan ;

Bethel, Paul A. ;

Box, Matthew ;

Butterworth, Sam ;

Colclough, Nicola ;

Chorley, Christopher G. ;

Chuaqui, Claudio ;

Cross, Darren A. E. ;

Dakin, Les A. ;

Debreczeni, Judit E. ;

Eberlein, Cath ;

Finlay, M. Raymond V. ;

Hill, George B. ;

Grist, Matthew ;

Klinowska, Teresa C. M. ;

Lane, Clare ;

Martin, Scott ;

Orme, Jonathon P. ;

Smith, Peter ;

Wang, Fengjiang ;

Waring, Michael J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) :7025-7048

← 1 →